RGS13
Regulator of G-protein signaling 13
Also known as: RGS13_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O14921
- Gene
- RGS13
- Ensembl
- ENSG00000127074
- Chromosome
- 1
- Canonical length
- 159 aa
- Protein class
- Predicted intracellular proteins
OverviewNCBI Gene
The protein encoded by this gene is a member of the regulator of G protein signaling (RGS) family. RGS family members share similarity with S. cerevisiae SST2 and C. elegans egl-10 proteins, which contain a characteristic conserved RGS domain. RGS proteins accelerate GTPase activity of G protein alpha-subunits, thereby driving G protein into their inactive GDP-bound form, thus negatively regulating G protein signaling. RGS proteins have been implicated in the fine tuning of a variety of cellular events in response to G protein-coupled receptor activation. The biological function of this gene, however, is unknown. Two transcript variants encoding the same isoform exist. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
159 residues, UniProt reviewed canonical sequence.
>O14921|RGS13
1 MSRRNCWICK MCRDESKRPP SNLTLEEVLQ WAQSFENLMA TKYGPVVYAA YLKMEHSDEN
61 IQFWMACETY KKIASRWSRI SRAKKLYKIY IQPQSPREIN IDSSTRETII RNIQEPTETC
121 FEEAQKIVYM HMERDSYPRF LKSEMYQKLL KTMQSNNSFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RGS13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 45 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 45 nTPM
- tonsil: 33 nTPM
- appendix: 9 nTPM
- small intestine: 5.3 nTPM
- lung: 3.7 nTPM
- gallbladder: 3.4 nTPM
Single-cell type
- mast cells: 595 nCPM
- tuft cells: 588 nCPM
- pdcs: 123 nCPM
- thymocytes: 42 nCPM
- cardiomyocytes: 24 nCPM
- plasma cells: 17 nCPM
Immune cell
- basophil: 6.9 nTPM
- memory B-cell: 0.1 nTPM
- naive B-cell: 0.1 nTPM
- plasmacytoid DC: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- thalamus: 0.2 nTPM
- hypothalamus: 0.1 nTPM
- medulla oblongata: 0.1 nTPM
- midbrain: 0.1 nTPM
- pons: 0.1 nTPM
- amygdala: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.39
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.07
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- G protein-coupled receptor signaling pathway
- negative regulation of G protein-coupled receptor signaling pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RGS13 as an antibody target. Whether an autoantibody or antibody against RGS13 could matter depends on whether native RGS13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RGS13 is annotated at the cell surface, where native RGS13 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label RGS13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...